Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive

@article{Han2014ExpertOO,
  title={Expert opinion on a flexible extended regimen of drospirenone/ethinyl estradiol contraceptive},
  author={Leo Han and J. Jensen},
  journal={Expert Opinion on Pharmacotherapy},
  year={2014},
  volume={15},
  pages={2071 - 2079}
}
Introduction: Oral contraceptives are often prescribed in extended or continuous forms in order to manage menstrual bleeding and menstrual-related side effects. However, with extended regimens, unscheduled intracycle bleeding can become problematic. Flexible extended dosing of a contraceptive containing drospirenone (DRSP) and ethinyl estradiol (EE) was designed to improve bleeding profiles during extended cycles through active management of bleeding symptoms. Areas covered: We examine the… Expand
Advances in pharmacotherapy for treating endometriosis
TLDR
The treatments most recently proposed for endometriosis will be described in detail, including gonadotropin-releasing hormone (GnRH) antagonists, aromatase inhibitors (AIs) and the flexible extended combined oral contraceptive. Expand
Treatment of pain associated with deep endometriosis: alternatives and evidence.
TLDR
Surgical excision of DIE should be considered in patients with pain symptoms persisting after first-line hormonal therapies, and the benefits of surgery in terms of pain improvement should be always balanced with the risk of intraoperative complications. Expand
Sexuality and Disabil ity in Adolescents
When caring for adolescents, providers may feel ill equipped to address issues of sexuality. In part, this may reflect the tendency to equate “sexuality” with “sexual intercourse.” Sexual developmentExpand
Sexuality and Disability in Adolescents.
TLDR
The medical provider may support healthy sexual development through education, anticipatory guidance, menstrual and contraceptive management, and by expanding the notion of sexuality to include a broader conceptualization of sexual behavior and expression. Expand
Regulation of Cervical Mucus Secretion

References

SHOWING 1-10 OF 49 REFERENCES
Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
TLDR
A flexible(MIB) dosing regimen of EE 20 mcg/drospirenone 3 mg is associated with good contraceptive efficacy and fewer bleeding/spotting days than the conventional 24/4 regimen. Expand
Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
TLDR
The flexibleMIB regimen allows women to extend their menstrual cycle and manage their intracyclic (breakthrough) bleeding and is associated with statistically significantly fewer bleeding/spotting days and fewer withdrawal bleeding episodes vs EE/DRSP in a conventional 28-day regimen. Expand
Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.
TLDR
The regimen continuously inhibited menses, increased the incidence of amenorrhea over time and, except for a subset of women, decreased the number of bleeding and spotting days. Expand
Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
TLDR
EE/DRSP in a flexible extended regimen with management of intracyclic (breakthrough) bleeding is well-tolerated and, when administered for up to 2 years, has a good safety profile comparable to other estrogen/progestogen oral contraceptives. Expand
Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.
TLDR
The drsp 3 mg/EE 20 mcg oral contraceptive in a 24/4 regimen was associated with greater ovarian suppression (despite intentional dosing error), which results in decreased hormonal fluctuations, and may increase contraceptive efficacy with the low-dose formulation. Expand
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
TLDR
The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication. Expand
A multicenter, randomized study of an extended cycle oral contraceptive.
TLDR
This study demonstrated that Seasonale, 91-day extended cycle OC containing 84 days of 30 microg EE/150 microg LNG followed by 7 days of placebo, was effective, safe and well tolerated. Expand
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone
TLDR
The treatment was well tolerated with an excellent safety profile and the majority of women (86%) stated that they were satisfied or very satisfied with the treatment and over 70% of women would have continued with the study medication. Expand
Continuous Combination Oral Contraceptive Pills to Eliminate Withdrawal Bleeding: A Randomized Trial
TLDR
Extension of the 28-day oral contraceptive cycle to continuous use with a low-estrogen dose combination oral birth control pill resulted in significantly fewer bleeding days. Expand
Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
TLDR
Extending the established 24/4-day regimen of EE 20 µg/DRSP 3 mg does not change the known steady-state PK of EE and DRSP, suggesting that the clinical efficacy is also similar, in line with the published clinical results from this study. Expand
...
1
2
3
4
5
...